Growth in asthmatic children treated with fluticasone propionate

    loading  Checking for direct PDF access through Ovid

Abstract

Objective

To determine whether inhaled fluticasone propionate has long-term effects on growth in children with persistent asthma.

Study design

In a double-blind, randomized, parallel-group, multicenter study, 325 prepubescent children with persistent asthma and normal growth rates were treated with placebo or inhaled fluticasone propionate powder 50 micro g or 100 micro g administered twice daily by a breath-actuated device for 1 year. Growth was evaluated monthly, whereas other safety variables and pulmonary function were evaluated periodically.

Results

The prepubescent patients showed no statistically significant differences in mean height, mean growth velocity, or mean skeletal age between any of the treatment groups at any time. Over a period of 1 year, mean height (+/- SE) increased 6.15 +/- 0.17 cm in the placebo group, 5.94 +/- 0.16 cm in the fluticasone propionate 50 micro g group, and 5.73 +/- 0.13 cm in the fluticasone propionate 100 micro g group (p = 0.308, overall).

Conclusions

Prepubescent children treated with fluticasone propionate 50 micro g and 100 micro g administered twice daily for 1 year grew at rates similar to placebo-treated control subjects and at rates equal to expected growth velocity for age. (J Pediatr 1998;132:472-7.)

Related Topics

    loading  Loading Related Articles